Mounjaro is an injectable once-weekly GIP/GLP-1 receptor agonist for adults with Type 2 in a single dose pre-filled pen. 

For more information visit Lilly

Device Type:
Medicine Pen
Reusable Disposable:
Disposable (Single dose only)
Medicine Type:
Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. 
Insulin Type:
Dose Delivery:
  • 2.5 mg per 0.5 mL
  • 5 mg per 0.5 mL
  • 7.5 mg per 0.5 mL
  • 10 mg per 0.5 mL
  • 12.5 mg per 0.5 mL
  • 15 mg per 0.5 mL

Largest Dose Possible:
15 mg/0.5 ml
Total Capacity:
  • 2.5 mg per 0.5 mL
  • 5 mg per 0.5 mL
  • 7.5 mg per 0.5 mL
  • 10 mg per 0.5 mL
  • 12.5 mg per 0.5 mL
  • 15 mg per 0.5 mL
Memory Function:
Audible Click:
Assistive Dexterity Issue Options:

Manufacturer Resources

Other Programs

For Patients



  • The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. 
  • After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.  If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly. 
  • If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).


Important Administration Instructions

  • Prior to initiation, train patients and caregivers on proper injection technique [see Instructions for Use].

  • Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose).

  • Administer MOUNJARO once weekly, any time of day, with or without meals.

  • Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.

  • Rotate injection sites with each dose.

  • Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.

  • When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject
    MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other. 

January 2024

The Danatech Digest

Join 18,000+ professionals who get our latest diabetes technology updates



This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.

ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.

Our Sponsors